Cyclophosphamide
Sold as Cyclocord, Endoxan
N,N-Bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
Drag to rotate. Structure from PubChem CID 2907.
Background
Registration
- Applicants
- 3
- Registrations
- 7
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Accord Healthcare (Pty) Ltd | Cyclocord | 1 g, 500 mg | 560922, 560923 | S4 | None |
| Baxter Healthcare South Africa (Pty) Ltd2 of 3 cancelled | Endoxan | 1 g, 50 mg, 500 mg | A380593, H2769, H2772 | S4 | None |
| Sanofi-aventis South Africa (Pty) LtdCertificate held by Baxter Healthcare South Africa (Pty) Ltd | Endoxan | 50 mg, 200 mg | H2770, H2771 | S4 | PIPIL |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Cyclocord 500 MG EACH VIAL CONTAINS CYCLOPHOSPHAMIDE MONOHYDRATE 500,0 mg | 500 mg | 56092256/26/0922 | Registered | S4 | None |
| Cyclocord 1 g EACH VIAL CONTAINS CYCLOPHOSPHAMIDE MONOHYDRATE 1,0 g | 1 g | 56092356/26/0923 | Registered | S4 | None |
| Endoxan 50 MG tablets EACH TABLET CONTAINS CYCLOPHOSPHAMIDE 50,0 mg | 50 mgTablets | A380593A38/26/0593 | Registered | S4 | None |
| Endoxan injection 500 MG EACH VIAL CONTAINS CYCLOPHOSPHAMIDE A 500,0 mg | 500 mgInjection | H2769 | Cancelled | S4 | None |
| Endoxan EACH TABLET CONTAINS CYCLOPHOSPHAMIDE A 50 mg | 50 mgTablets | H2770Approved 21 September 2022 | Old Medicine | S4 | PIPIL |
| Endoxan injection 200 MG EACH VIAL CONTAINS CYCLOPHOSPHAMIDE A 200 mg | 200 mgInjection | H2771 | Old Medicine | S4 | None |
| Endoxan injection 1 g EACH VIAL CONTAINS CYCLOPHOSPHAMIDE A 1,0 g | 1 gInjection | H2772 | Cancelled | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Cyclophosphamide monohydrate
S4: Cyclophosphamide
- unless listed in another Schedule.
Consolidated Schedules 06 July 2026, line 5905
Pharmacological class: Cytostatic agents (class 26)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Endoxan, Sanofi-aventis South Africa (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.